sorafenib has been researched along with B16 Melanoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, L; Dijkstra, HP; Friedlos, F; Gaulon, C; Gill, A; Hedley, D; Kirk, R; Manne, H; Marais, R; Ménard, D; Moreno-Farre, J; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Ogilvie, L; Raynaud, FI; Springer, CJ; Suijkerbuijk, BM; Taylor, RD; Whittaker, S; Zambon, A | 1 |
| Adams, R; Adhikari, S; Aertgeerts, K; Afroze, R; Blackburn, C; Calderwood, EF; Chau, R; Chouitar, J; Duffey, MO; England, DB; Farrer, C; Forsyth, N; Galvin, KM; Garcia, K; Gaulin, J; Gould, AE; Greenspan, PD; Guo, R; Harrison, SJ; Huang, SC; Iartchouk, N; Janowick, D; Kim, MS; Kulkarni, B; Langston, SP; Liu, JX; Ma, LT; Menon, S; Mizutani, H; Paske, E; Renou, CC; Rezaei, M; Rowland, RS; Sintchak, MD; Smith, MD; Stroud, SG; Tian, Y; Tregay, M; Veiby, OP; Vos, TJ; Vyskocil, S; Williams, J; Xu, T; Yang, JJ; Yano, J; Zeng, H; Zhang, DM; Zhang, Q | 1 |
| Cai, M; Huang, W; Xing, Y; Zhu, L; Zhuo, J | 1 |
| Fu, F; Kong, X; Sun, S; Wang, H; Wang, N; Yao, J; Zhang, J | 1 |
| Argilés, JM; Busquets, S; López-Soriano, FJ; Penna, F; Toledo, M | 1 |
| Brandon, VL; Chen, MY; Hsu, LC; Jandial, R; Jove, R; Li, G; Lin, J; Yang, F; Yin, Y; Zou, Z | 1 |
| Jalkanen, S; Joensuu, H; Laukkanen, MO; Laurila, JP; Salmi, M | 1 |
| Lee, WM; Tsai, JH | 1 |
| Bawa, O; Benatsou, B; Koscielny, S; Lassau, N; Leguerney, I; Massard, C; Opolon, P; Peronneau, P; Roche, A; Rodrigues, M; Rouffiac, V; Thalmensi, J | 1 |
9 other study(ies) available for sorafenib and B16 Melanoma
| Article | Year |
|---|---|
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; In Vitro Techniques; Melanoma, Experimental; Mice; Mice, Nude; Microsomes, Liver; Mutation; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Pyridines; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Melanoma, Experimental; Mice; Mice, Nude; Models, Molecular; Mutation; Proto-Oncogene Proteins B-raf; Stereoisomerism; Structure-Activity Relationship; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2011 |
Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Movement; Cell Proliferation; Drug Carriers; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gold; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; MCF-7 Cells; Melanoma, Experimental; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Zonula Occludens-1 Protein | 2021 |
Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Design; ErbB Receptors; Humans; Melanoma, Experimental; Mice, Inbred C57BL; Molecular Docking Simulation; Protein Binding; Quinazolines; Sorafenib; Thiourea; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Wasting Syndrome | 2014 |
Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Convection; Heterografts; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Transcriptional Activation | 2016 |
Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
Topics: Animals; Cell Movement; Female; Indoles; Leukocytes; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Transendothelial and Transepithelial Migration | 2016 |
Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.
Topics: Angiopoietin-1; Animals; Apoptosis; Benzenesulfonates; Doxycycline; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; In Vitro Techniques; Melanoma, Experimental; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, TIE-2; Recombinant Proteins; Signal Transduction; Sorafenib; Transfection | 2009 |
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Contrast Media; Drug Administration Schedule; Extracellular Fluid; Female; Fiber Optic Technology; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Phospholipids; Pressure; Pyridines; Regional Blood Flow; Sorafenib; Sulfur Hexafluoride; Time Factors; Transducers, Pressure; Ultrasonography, Doppler | 2012 |